Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/51747

TitleMultiple sclerosis: Association of gelatinase B/matrix metalloproteinase-9 with risk and clinical course the disease
Author(s)Valado, Ana
Leitão, Maria João
Martinho, António
Pascoal, Rui
Cerqueira, João José
Correia, Inês
Batista, Sónia
Sousa, Lívia
Baldeiras, Inês
KeywordsMultiple sclerosis
MMP-9
−1562C/T polymorphism
Serum
IFN-beta therapy
Issue date4-Jan-2017
PublisherElsevier
JournalMultiple Sclerosis and Related Disorders
CitationValado, A., Leitão, M. J., Martinho, A., Pascoal, R., Cerqueira, J., Correia, I., ... & Baldeiras, I. (2017). Multiple sclerosis: Association of gelatinase B/matrix metalloproteinase-9 with risk and clinical course the disease. Multiple sclerosis and related disorders, 11, 71-76
Abstract(s)Background: Multiple sclerosis (MS) is an autoimmune disease characterized by inflammation and axonal degeneration of the central nervous system and a leading cause of disability in young adults. The matrix metalloproteinases in general and specially gelatinase B/metalloproteinase-9 (MMP-9) plays a role in the pathogenesis of multiple sclerosis. Objective: To investigate the presence of the MMP-9 1562 C/T polymorphism in a Portuguese population of MS patients and assess its impact in susceptibility and course of the disease. The relation of MMP-9 serum levels with the polymorphism and with clinical and therapeutic factors will also be assessed. Methods: Our study included 355 Caucasian individuals distributed as MS patients (n=169) and controls (n=186). Samples were genotyped for 1562 C/T polymorphism by PCR-RFLP analysis. MMP-9 concentration in serum was analyzed using a commercially available enzyme-linked immunosorbent assay. Results: A significant increase in T-allele frequency was found in female MS patients, but not in the total patient population. No association between the presence of the polymorphism and disease progression was found. MMP-9 serum concentrations were increased in patients, and although not influenced by the 1562 C/T polymorphism, were modified by INF-beta therapy. Conclusion: Although we did not find an association of this polymorphism with disease susceptibility or prognosis, MMP-9 appears to be a good therapeutic response marker for multiple sclerosis.
TypeArticle
URIhttp://hdl.handle.net/1822/51747
DOI10.1016/j.msard.2016.12.003
ISSN2211-0348
Publisher versionhttp://www.msard-journal.com/article/S2211-0348(16)30225-5/abstract
Peer-Reviewedyes
AccessOpen access
Appears in Collections:ICVS - Artigos em Revistas Internacionais com Referee

Files in This Item:
File Description SizeFormat 
1-s2.0-s2211034816302255-main.pdf392,92 kBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID